New combo therapy aims to boost immune attack on hard-to-treat prostate cancer
NCT ID NCT07219147
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This early-phase trial studies whether adding a targeted radiation drug (Lu-PSMA-617) to an immune cell therapy (Sipuleucel-T) is safe and works better than the radiation drug alone for men with metastatic castration-resistant prostate cancer. About 30 participants will receive either the combination or the radiation drug alone. The goal is to see if the combination triggers a stronger immune response against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.